Loading company…
Chongqing developer of tumor immune cell therapies, including CAR-T, TCR-T, CAR-NK and TIL products, founded in 2016.
TCRCure Biopharma Ltd. develops CAR-T, TCR-T, CAR-NK and TIL immune cell therapies, along with immunodiagnosis services for patients with lung, liver and cervical cancer. It works with hospitals including Sun Yat-sen Medical University Cancer Hospital and West China Hospital. Established in 2016 in Chongqing, China, the company has more than 150 employees, passed a GMP audit in November 2020, and started a TC-E202 phase I study in December 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in